Incyte Corp Company Profile
What is the competitive landscape for INCYTE CORP
INCYTE CORP has four approved drugs.
There are forty-one US patents protecting INCYTE CORP drugs.
Summary for Incyte Corp
| US Patents: | 41 |
| Tradenames: | 4 |
| Ingredients: | 2 |
| NDAs: | 4 |
| Patent Litigation for Incyte Corp: | See patent lawsuits for Incyte Corp |
| PTAB Cases with Incyte Corp as petitioner: | See PTAB cases with Incyte Corp as petitioner |
Drugs and US Patents for Incyte Corp
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Incyte Corp | JAKAFI XR | ruxolitinib phosphate | TABLET, EXTENDED RELEASE;ORAL | 217180-002 | May 1, 2026 | RX | Yes | No | 9,206,187 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Incyte Corp | JAKAFI XR | ruxolitinib phosphate | TABLET, EXTENDED RELEASE;ORAL | 217180-003 | May 1, 2026 | RX | Yes | No | 11,576,864*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Incyte Corp | JAKAFI XR | ruxolitinib phosphate | TABLET, EXTENDED RELEASE;ORAL | 217180-001 | May 1, 2026 | RX | Yes | No | 9,814,722 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Incyte Corp | OPZELURA | ruxolitinib phosphate | CREAM;TOPICAL | 215309-001 | Sep 21, 2021 | RX | Yes | Yes | 9,974,790*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for INCYTE CORP drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg | ➤ Subscribe | 2015-12-17 |
International Patents for Incyte Corp Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Mexico | 338228 | ⤷ Start Trial |
| Croatia | P20160717 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2014007951 | ⤷ Start Trial |
| Israel | 317061 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Incyte Corp Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2861595 | PA2021519 | Lithuania | ⤷ Start Trial | PRODUCT NAME: PEMIGATINIBAS ARBA JO FARMACISKAI PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/21/1535 20210326 |
| 2455382 | CR 2017 00018 | Denmark | ⤷ Start Trial | PRODUCT NAME: RUXOLITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER RUXOLITINIB FOSFAT; REG. NO/DATE: EU/1/12/773/001-016/C(2015)1740 20150313 |
| 2455382 | 201740011 | Slovenia | ⤷ Start Trial | PRODUCT NAME: RUXOLITINIB OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; NATIONAL AUTHORISATION NUMBER: EU/1/12/773/001-016; DATE OF NATIONAL AUTHORISATION: 20150311; AUTHORITY FOR NATIONAL AUTHORISATION: EU |
| 1966202 | PA2013002,C1966202 | Lithuania | ⤷ Start Trial | PRODUCT NAME: RUXOLITINIBUM; REGISTRATION NO/DATE: EU/1/12/773/001-EU/1/12/773/003, 2 00120823 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
